Bob Duggan’s success shows you don’t need a Ph.D., or even a college education, to make money in the complex world of biotech ...

Investing in biotech stocks isn't for everyone. An unsuccessful clinical trial can cause a huge decline. The competition is ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

A South San Francisco biotech company that was co-founded by an OHSU scientist six years ago closed a $68 million financing ...

The new firm is raising a $150 million fund to back startups around science emerging outside Boston and San Francisco.

CARSON CITY, NV, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (OTC PINKS: PHBI) ("Pharmagreen" or the "Company") is pleased to announce ...

A dark money anti-pharma bus —A rare disease treatment approval for Zevra —An FTC lawsuit against pharmacy benefit managers ...

An open letter written to vaccine manufacturer Bharat Biotech International Ltd and to the Indian Council of Medical Research ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

This week on meet the fund managers, we’re hearing from Ailsa Craig, co-portfolio manager of International Biotechnology ...

Moleculin Biotech shares were up 12% to $2.65 after the company said it saw positive in vivo efficacy data of Annamycin in lung metastatic models of sarcoma. The stock is approaching its 52-week low ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...